LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Market Closed 04-24 16:00:00 EDT

1.07

-0.02

-1.83%

盘后1.10

+0.03+2.56%

19:59 EDT

High1.13	Low1.07	Vol1.16M
Open1.13	D1 Closing1.09	Amplitude5.50%
Mkt Cap189.33M	Tradable Cap116.80M	Total Shares176.95M
T/O1.26M	T/O Rate1.06%	Tradable Shares109.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":1.07,"timestamp":1777060800000,"preClose":1.09,"halted":0,"volume":1159810,"hourTrading":{"tag":"盘后","latestPrice":1.0974,"preClose":1.07,"latestTime":"19:59 EDT","volume":15312,"amount":16792.85,"timestamp":1777075164861,"change":0.0274,"changeRate":0.025607,"amplitude":0.037383},"delay":0,"changeRate":-0.018348623853211024,"floatShares":109163095,"shares":176945972,"eps":-0.692213,"marketStatus":"Market Closed","change":-0.02,"latestTime":"04-24 16:00:00 EDT","open":1.13,"high":1.13,"low":1.07,"amount":1264626.436978,"amplitude":0.055046,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.692213,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":1.09,"preHourTrading":{"tag":"盘前","latestPrice":1.14,"preClose":1.09,"latestTime":"08:55 EDT","volume":1106,"amount":1287.2432062,"timestamp":1777035350170,"change":0.05,"changeRate":0.045872,"amplitude":0.057982},"postHourTrading":{"tag":"盘后","latestPrice":1.0974,"preClose":1.07,"latestTime":"19:59 EDT","volume":15312,"amount":16792.85,"timestamp":1777075164861,"change":0.0274,"changeRate":0.025607,"amplitude":0.037383},"volumeRatio":1.2077139298121753},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2630787877","title":"Lucid Diagnostics Raises Capital Through Direct Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2630787877","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630787877?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:47","pubTimestamp":1777067247,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has shared an update. On April 24, 2026, Lucid Diagnostics closed an underwritten registered direct offering of 18,00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-raises-capital-through-direct-share-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-raises-capital-through-direct-share-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","BK4555","BK4082","BK4596","LCID","LUCD","LCIZ","BK4551","LCDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840972","title":"Lucid Diagnostics closes USD 18 million follow-on offering of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840972","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629840972?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:27","pubTimestamp":1777040876,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics closed an underwritten registered direct offering of 18,000,000 common shares at USD 1 per share.Gross proceeds totaled about USD 18 million, including a USD 15 million anchor investment from a fundamental institutional investor.Net proceeds earmarked for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL7lNzqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629184066","title":"Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2629184066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629184066?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:23","pubTimestamp":1777040638,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nTUA61W3DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629545438","title":"BUZZ-U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2629545438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629545438?lang=en_us&edition=fundamental","pubTime":"2026-04-24 01:44","pubTimestamp":1776966278,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, United Rentals, cannabis stocks Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Cal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL6N4160QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LULU","ASGN","LUCD","NXPI","ADBE","ALT","INTU","PSKY","TXN","ELMT","AAL","MCHP","HAS","MBLY","MSFT","ON","QS","NEE","LULG","WST","INTC","KDP","TSLA","CSX","APLZ","HELE","FCX","ROP","SIRI","AALG","TMO","CRSH","NOW","RNA","07766","REGN","HON","LMT","AXP","KREF","CMCSA","PCG","NFLX","APLD","HLX","ADI","EFOR","LRCX","CRWD","IBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629834886","title":"Lucid Diagnostics prices 18M shares at $1.00 in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2629834886","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629834886?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:35","pubTimestamp":1776947746,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics (LUCD) announced the pricing of an underwritten registered direct offering of 18M common shares at a purchase price of $1.00 per ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-prices-18m-shares-at-1-00-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-prices-18m-shares-at-1-00-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","BK4555","LCID","LCDL","BK4596","BK4082","BK4551","LCIZ","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629831404","title":"Lucid Diagnostics prices $18 million stock offering at $1 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629831404","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629831404?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:33","pubTimestamp":1776947630,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics priced an underwritten registered direct offering of 18,000,000 common shares at USD 1 per share.Gross proceeds expected at about USD 18 million before fees.Net proceeds earmarked for working capital and general corporate purposes.Closing expected on or about April 24, 2026, subject to customary conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire  on April 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL5ZYQjj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629319908","title":"Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2629319908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629319908?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:30","pubTimestamp":1776947403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nTUA38ZYKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","LUCD","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629779176","title":"Lucid Diagnostics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629779176","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629779176?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:10","pubTimestamp":1776719421,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics will hold annual shareholder meeting on June 24, 2026 in virtual format.Shareholders will vote on election of three Class B directors.Meeting agenda includes proposal to increase authorized common stock by 100,000,000 shares to 400,000,000.Investors will also vote on ratification of CBIZ as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLnvmfp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627632974","title":"Lucid Diagnostics files Form 3 for Chief Medical Officer Victoria Tou-ho Lee","url":"https://stock-news.laohu8.com/highlight/detail?id=2627632974","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627632974?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:09","pubTimestamp":1776110982,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics filed Form 3 showing Chief Medical Officer Victoria Tou-ho Lee holds 650,000 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL3DW5sx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626184971","title":"PAVmed unit Lucid Diagnostics to join Needham Virtual Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2626184971","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626184971?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:11","pubTimestamp":1775736670,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics, PAVmed subsidiary, scheduled a fireside chat at 25th Annual Needham Virtual Healthcare Conference for April 16, 2026 at 10:15 a.m. EDT.Chairman and CEO Lishan Aklog will represent Lucid at event.Webcast will run live via Lucid investor relations site.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL40nb7m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506671","title":"Press Release: PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506671?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:01","pubTimestamp":1775131260,"startTime":"0","endTime":"0","summary":"Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc.  , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.\"PAVmed has already established a strong foundation with its existing medi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","BK4022","R","BK4232","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623175383","title":"PAVmed Inc - Q4 2025 Non-Gaap Adj Loss $0.9 Mln, $1.05 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623175383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623175383?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:07","pubTimestamp":1774872423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0Q5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623127473","title":"Press Release: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623127473","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623127473?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership. Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission. Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base. Conference call and webcast to be held today, March 30, at 8:30 AM EST. NEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc.  , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc.   and Veris Health Inc. , and reported financial results for the fourth quarter and year ended December 31, 2025.The webcast will take place on Monday, March 30, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternatively, to access the conference call by tel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCIZ","BK4551","BK4099","LCID","BK4022","BK4596","BK4232","LCDL","BK4555","BK4082","PAVM","R","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622578891","title":"Lucid Diagnostics Inc: May Offer and Sell Shares of Common Stock of up to $25 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622578891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622578891?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:02","pubTimestamp":1774558967,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E12D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622634698","title":"Lucid Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622634698","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622634698?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531932,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc reports results for the quarter ended December 31 - Earnings SummaryLucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E1BP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850574","title":"Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850574?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:37","pubTimestamp":1774528659,"startTime":"0","endTime":"0","summary":"In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Lucid Diagnostics, with a price target of $3.00. Acco...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LUCD","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852446","title":"Press Release: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852446","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852446?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:00","pubTimestamp":1774526400,"startTime":"0","endTime":"0","summary":"Processed 3,664 EsoGuard tests and recognized 4Q25 revenue of $1.5 million. Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detection. Conference call and webcast to be held today, March 26, at 8:30 AM EST. NEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.   a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.  , today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2025.The webcast will take place on Thursday, March 26, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCID","R","BK4082","BK4022","BK4555","BK4099","BK4596","BK4232","LCDL","BK4551","LCIZ","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622400784","title":"Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622400784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622400784?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:57","pubTimestamp":1774472229,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.Cash used in operations was USD 46.5 million.Ended the year with cash on hand of USD 34.7 million.Business updates included an 18-month real-world analysis covering about 12,000 patients.Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to gener","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2gf0bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621906227","title":"Lucid Diagnostics Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621906227","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621906227?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:43","pubTimestamp":1774356185,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc  expected to post a loss of10cents a share - Earnings Preview Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to  show a rise in quarterly revenue when it reports  results on Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C1E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUCD","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618132760","title":"Lucid Diagnostics schedules fourth-quarter and full-year 2025 business update call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132760?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:10","pubTimestamp":1773321026,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics will hold a fourth quarter and full year 2025 business update conference call and webcast on March 26, 2026, at 8:30 AM ET. The webcast will be available at luciddx.com. Lishan Aklog will provide a business update during the call. Dennis McGrath will discuss fourth quarter 2025 financial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL1YXbK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":-0.144},{"period":"1month","weight":-0.1008},{"period":"3month","weight":-0.1157},{"period":"6month","weight":-0.1641},{"period":"1year","weight":-0.1955},{"period":"ytd","weight":-0.0183}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.035074},{"month":2,"riseRate":0.8,"avgChangeRate":0.165426},{"month":3,"riseRate":0.4,"avgChangeRate":-0.121674},{"month":4,"riseRate":0.4,"avgChangeRate":-0.088036},{"month":5,"riseRate":0.5,"avgChangeRate":0.04431},{"month":6,"riseRate":0.25,"avgChangeRate":-0.075357},{"month":7,"riseRate":0.5,"avgChangeRate":0.031793},{"month":8,"riseRate":0.75,"avgChangeRate":0.032951},{"month":9,"riseRate":0.25,"avgChangeRate":-0.178841},{"month":10,"riseRate":1,"avgChangeRate":0.186111},{"month":11,"riseRate":0.4,"avgChangeRate":-0.040647},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154424}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}